This mechanism is mediated through the Aryl hydrocarbon receptor (AhR) of tumor cells, and AhR inhibitors counteracts the ability of ILA to inhibit CRC growth in vivo and in vitro. The gene discussed is AHR; the disease is colorectal carcinoma.